The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage

• Published in: British journal of neurosurgery Vol. 25; no. 1; pp. 117 - 119
• Main Authors: Hertle, Daniel N., Hähnel, Stefan, Richter, Götz M., Unterberg, Andreas, Sakowitz, Oliver W., Kiening, Karl L.
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01-02-2011; Taylor & Francis Ltd
• Subjects: Aged; Anticoagulants; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Blood Coagulation Disorders - drug therapy; Blood platelets; Cerebral Hemorrhage - chemically induced; Cerebral Hemorrhage - drug therapy; Chondroitin Sulfates - administration & dosage; Chromosome Breakage; Chromosome Disorders - chemically induced; Chromosome Disorders - drug therapy; Dermatan Sulfate - administration & dosage; Hemorrhage; Heparin, Low-Molecular-Weight - adverse effects; Heparitin Sulfate - administration & dosage; Humans; Male; Medical treatment; Neurosurgery; Thrombocytopenia - chemically induced; Thrombocytopenia - congenital; Thrombocytopenia - drug therapy; Thrombosis; Treatment Outcome; Veins & arteries
• ISSN: 0268-8697; 1360-046X
• DOI: 10.3109/02688697.2010.502266

This study presents a case of bifrontal intracerebral haemorrhage in a patient with heparin-induced thrombocytopenia type II (HIT II). HIT II was induced by treatment with low-molecular-weight heparin for recurrent deep vein thrombosis caused by essential thrombocytosis and accompanied by hepatic thromboembolism. This patient was treated with platelet substitution and neurosurgical haematoma evacuation. Anticoagulation with 2500 units danaparoid per day was sufficient for therapy of thrombosis and no rebleeding occurred.